Roivant's Brepocitinib Data Uplifts Stock 18% Amid Cutaneous Sarcoidosis Treatment Breakthrough

Roivant's subsidiary, Priovant Therapeutics, reported positive Phase 2 BEACON data in cutaneous sarcoidosis, leading to an 18% increase in Roivant's stock. Roivant owns ~74% of Priovant. The data supports the development of brepocitinib, an oral Janus kinase (JAK) inhibitor, as a potential treatment for the condition. Roivant's stock price has risen following the announcement.